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Comments on 'HbA 1c predicts the likelihood of having impaired glucose tolerance in high-risk patients with normal fasting plasma glucose'
In a recent article, Geberhiwot et al. 1 dealt with combining haemoglobin A 1C (HbA 1c ) and fasting plasma glucose (FPG) in high-risk populations in order to identify patients requiring an oral glucose tolerance test (OGTT), which we agree may be the best tool to detect these populations. However, in response to some of the statements and calculations in the paper, we wish to make some clarifying comments.
Firstly, there is no description of how to estimate the optimal cut-o¡ point using ROC analysis. Is it slope of the ROC curve, sensitivity, speci¢city or weighting of false positive against false negative? With their values of sensitivity (72%) and speci¢city (77%), there will still be 28% false negatives and 23% false positives, which with the number of patients in the investigation is 52 Â0.72 ¼37 true positive individuals and 173 Â0.23 ¼40 false positive individuals. Consequently, there will be more false positive than true positive individuals.
Secondly, from the text it is explained that in patients with FPGp6.0 mmol/l and HbA 1c levels o5.0%, abnormal glucose tolerance can be ruled out 'with 100% certainty'. Using the data shown in Figure 1 in their paper for HbA 1c o5.0%, the sensitivity is approximately 95%, and knowing that the total number of IGT and diabetics is 52, there are still two or three of these patients below this value, so it is not 'with 100% certainty', as concluded in their text.
Thirdly, when reporting the variability of the results, although the inter-assay coe⁄cients of variation for glucose and HbA 1c are expressed, the bias or traceability of the method is not documented. Some of us 2 used the same method to ¢nd a logarithmic distribution of HbA 1c values from a low-risk population for diabetes. In this study, the traceability is fully explained and documented, and the geometric mean of this low-risk population is 5.6% HbA 1c (i.e. half of this low-risk population would be considered quali¢ed for OGTT according to Geberhiwot et al. 1 ), so from these results it looks as though their method has an analytical bias. Therefore, the results obtained in their study would not be transferable to other laboratories, even if they are using the same method.
Finally, a minor error: they write that the results are expressed as means7SEM; however, the description of age for men is 52.9712.0 years and for women 53.3713.5. Taking into account that SEM is calculated as s/sqrt(n), the standard deviations should be129 years for men and 141 for women. Natàlia Iglesias 1 , Per Hyltoft Petersen 2 , Lone GM Jørgensen 3 and Ivan Brandslund 3,4
